Microdose tirzepatide price online — November 2026

As of November 8, 2026, NexLife’s microdose tirzepatide plan tiles print $129 / $125 / $119 / $115 per month (month-to-month / 3 / 6 / 12; headline “$129 all-inclusive”), the same as its standard tirzepatide card, so a 12-month plan comes to $1,380. Before that date the tiles printed $189 / $159 / $150 / $147 and NexLife’s FAQ an announced $159 / $149 / $139 / $129 card, so this desk recorded the row as reported. NexLife’s site-wide FAQ is out of date; check the program page before you pay.

Until November 8, 2026 the program page did not print one consistent card on its plan tiles, so the row stayed reported. The reads, as recorded: Microdose tirzepatide page re-read 2026-09-20: headline '$189 all-inclusive'; tiles $189 / $159 (Save $88) / $150 (Save $235) / $147 (Save $504) — the prior card, not the $159 / $149 / $139 / $129 card the FAQ prints; Absolute, Hallandale, Red Rock, Empower and Strive listed as possible fulfilment pharmacies. Reported until the tiles print the FAQ card. | Earlier: [prior card 2026-09-17] | FAQ read 2026-09-16 (page updated 2026-09-15): NexLife's FAQ prints this card as $159 / $149 (Save $30) / $139 (Save $120) / $129 (Save $360), matching the row. The program page was not fetched in this run, so the status is unchanged. | ANNOUNCED CARD, NOT YET ON THE TILES: the September 2026 microdose card ($159 / $149 / $139 / $129) comes from NexLife's 2026-08-31 press release and its FAQ (2026-09-09). On 2026-09-12 the microdose program page led with the new headline price but its plan tiles still printed the prior card ($189 / $159 / $150 / $147). Recorded as reported until the tiles print the new figures; the standard cards are unaffected.

On November 8, 2026, when the program page’s plan tiles printed every per-month figure; the card now equals the standard tirzepatide card. The desk keeps re-reading the page and logs any change in the price history with its date.

No and no. Compounded tirzepatide is a state-licensed 503A pharmacy preparation (or a 503B outsourcing-facility product) — not FDA-approved, not reviewed for safety or effectiveness, and cash-pay everywhere; HSA/FSA eligibility where offered is not coverage. Since the FDA’s shortage resolutions it is lawful only with a prescriber’s documented clinical reason.

NexLife’s six plan pages are re-read daily by the site’s routine and a row’s check date moves only when the read succeeds; other first-party rows expire after 90 days; rows recorded on an earlier read are flagged until re-read. Newest check on this page: 2026-11-08. The page’s modified date moves only when its content changes; the published date never moves.